Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

You Make the Call: Reader Response

How readers responded to this month's You Make the Call question

Disclaimer: ASH does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this article is solely at your own risk.

Would you treat borderline anemic pregnant patients with oral or intravenous iron?
How would you treat a patient with acute promyelocytic leukemia and CNS disease?
What prophylactic treatment would you recommend for a basketball player who has had multiple episodes of hematoma?
Would you proceed with a 7/8 matched unrelated donor alloHCT in a patient with severe acquired aplastic anemia?
What second-line therapies would you recommend for Rosai-Dorfman disease following a modest partial response to prednisone?
Would you start a patient who presented with a left cerebrovascular accident likely due to oral contraceptive use on warfarin?
Would you refer patients whose bone marrow samples came back with mutations for genetic counseling and germline testing?
Would you extend anticoagulation in a patient who had a native aortic valve thrombus while on DHEA?
Would you add rituximab to standard of care in newly diagnosed hairy cell leukemia?
Would you conduct variant hemoglobin testing in a pediatric patient with iron deficiency?
Would you prescribe voxelotor to a patient with SCD who has a history of CVA and occlusive retinopathy?
How would you treat a patient who is in remission from CML but has positive cytogenetic and molecular tests?
How would you treat a female patient with a history of upper extremity DVT taking enoxaparin?
How would you treat a patient with end-stage lung cGVHD and worsening hypoxia?
When would you start phlebotomy for an asymptomatic patient with hemochromatosis?
How would you treat a patient with cold agglutinin disease and pathology consistent with MCL?
How would you treat a patient with UC and COVID vaccine-associated cerebral sinus thrombosis?
How would you treat a patient with an underlying bleeding disorder and CSF3R-mutated MDS/MPN-U?
What would you advise for a male patient with SCD receiving HU who is concerned about teratogenicity?
What would you recommend for a patient with essential thrombocythemia who has high platelet counts but no history of thrombosis?

Advertisement

Connect with us:

CURRENT ISSUE
May 2024

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement